Lung cancer, comorbidities, and medication: the infernal trio.
comorbidities
drug-drug interaction
lung cancer
polypharmacy
survival
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
08
2022
accepted:
25
09
2023
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
7
3
2024
Statut:
epublish
Résumé
Most patients with lung cancer are smokers and are of advanced age. They are therefore at high risk of having age- and lifestyle-related comorbidities. These comorbidities are subject to treatment or even polypharmacy. There is growing evidence of a link between lung cancer, comorbidities and medications. The relationships between these entities are complex. The presence of comorbidities and their treatments influence the time of cancer diagnosis, as well as the diagnostic and treatment strategy. On the other hand, cancer treatment may have an impact on the patient's comorbidities such as renal failure, pneumonitis or endocrinopathies. This review highlights how some comorbidities may have an impact on lung cancer presentation and may require treatment adjustments. Reciprocal influences between the treatment of comorbidities and anticancer therapy will also be discussed.
Identifiants
pubmed: 38450055
doi: 10.3389/fphar.2023.1016976
pii: 1016976
pmc: PMC10916800
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1016976Informations de copyright
Copyright © 2024 Pluchart, Chanoine, Moro-Sibilot, Chouaid, Frey, Villa, Degano, Giaj Levra, Bedouch and Toffart.
Déclaration de conflit d'intérêts
HP, SC, PB, GF, JV, and BD have nothing to disclose. A-CT received consulting fees and non-financial support from Astra Zeneca, BMS, MSD, Novartis, Boehringer Ingelheim, Roche, Pfizer. DMS received grants or contracts from any entity from Roche, Astra Zeneca, BMS, Boehringer Ingelheim, Abbvie, Pfizer; received consulting fees from Roche, Astra Zeneca, BMS, MSD, Lilly, Takeda, Boehringer Ingelheim, Abbvie, Becton Dickinson, Pfizer, Novartis; received non-financial support from Roche, Astra Zeneca, BMS, MSD, Lilly, Takeda, Boehringer Ingelheim and Pfizer. CC received grants or contracts from any entity, consulting fees and non-financial support from Astra Zeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Amgen. MGL received grants or contracts from any entity from Astra Zeneca, BMS; received consulting fees from Astra Zeneca, BMS, MSD; received non financial support from MSD, Takeda.